3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Neoplasms
115
Colorectal Neoplasms
97
Breast Neoplasms
90
Pancreatic Neoplasms
81
Leukemia, Myeloid, Acute
81
Recurrence
78
Neoplasm Metastasis
78
Prostatic Neoplasms
73
Melanoma
73
Ovarian Neoplasms
72
Multiple Myeloma
66
Stomach Neoplasms
60
Squamous Cell Carcinoma of Head and Neck
55
Lung Neoplasms
55
Triple Negative Breast Neoplasms
50
Glioblastoma
48
Lymphoma
47
Endometrial Neoplasms
43
Carcinoma, Hepatocellular
43
Advanced Solid Tumor
43
Precursor Cell Lymphoblastic Leukemia-Lymphoma
42
Lymphoma, Non-Hodgkin
41
Advanced Solid Tumors
37
Uterine Cervical Neoplasms
35
Small Cell Lung Carcinoma
35
Carcinoma, Renal Cell
34
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma, B-Cell
32
Sarcoma
29
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled